AU2019214977A1 - Anti-PD-1 antibodies - Google Patents
Anti-PD-1 antibodies Download PDFInfo
- Publication number
- AU2019214977A1 AU2019214977A1 AU2019214977A AU2019214977A AU2019214977A1 AU 2019214977 A1 AU2019214977 A1 AU 2019214977A1 AU 2019214977 A AU2019214977 A AU 2019214977A AU 2019214977 A AU2019214977 A AU 2019214977A AU 2019214977 A1 AU2019214977 A1 AU 2019214977A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- seq
- antigen
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPCT/CN2018/074916 | 2018-02-01 | ||
PCT/CN2018/074916 WO2019148410A1 (en) | 2018-02-01 | 2018-02-01 | Anti-pd-1 antibodies |
PCT/US2019/015932 WO2019152571A1 (en) | 2018-02-01 | 2019-01-31 | Anti-pd-1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019214977A1 true AU2019214977A1 (en) | 2020-08-13 |
Family
ID=67477905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019214977A Pending AU2019214977A1 (en) | 2018-02-01 | 2019-01-31 | Anti-PD-1 antibodies |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210032342A1 (zh) |
EP (1) | EP3746120A4 (zh) |
JP (1) | JP2021511806A (zh) |
KR (1) | KR20200115595A (zh) |
CN (1) | CN111670047A (zh) |
AU (1) | AU2019214977A1 (zh) |
BR (1) | BR112020015498A8 (zh) |
CA (1) | CA3089075A1 (zh) |
MX (1) | MX2020008122A (zh) |
WO (2) | WO2019148410A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
EP4076521A4 (en) * | 2019-12-20 | 2024-01-24 | Merck Sharp & Dohme LLC | METHODS OF TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPY AGENTS |
CA3176119A1 (en) * | 2020-06-02 | 2021-12-09 | Teijin Pharma Limited | Anti-igf-1 receptor humanized antibody |
CN116782937A (zh) * | 2020-12-10 | 2023-09-19 | 优特力克斯有限公司 | 抗pd-1抗体及其用途 |
JP2024508886A (ja) * | 2021-03-04 | 2024-02-28 | コード バイオセラピューティクス インコーポレイテッド | 抗体-オリゴヌクレオチドコンジュゲートを使用した標的化の増強 |
CN115466328A (zh) * | 2021-06-11 | 2022-12-13 | 广东菲鹏制药股份有限公司 | 抗pd-1人源化抗体或其抗原结合片段及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200703154B (en) * | 2004-10-01 | 2008-09-25 | Medarex Inc | Methods of treating CD30 positive lymphomas |
WO2007132461A2 (en) * | 2006-05-11 | 2007-11-22 | Ramot At Tel Aviv University Ltd. | Classification of protein sequences and uses of classified proteins |
PL2170959T3 (pl) * | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
US9868777B2 (en) * | 2013-06-10 | 2018-01-16 | Merck Sharp & Dohme Corp. | CMV neutralizing antigen binding proteins |
CN113698485A (zh) * | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
CN108368170B (zh) * | 2015-07-13 | 2022-04-15 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
CN106699888B (zh) * | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
WO2019148412A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
JP2022546922A (ja) * | 2019-07-30 | 2022-11-10 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗pd-1/lag3/tigit三重特異性抗体および抗pd-1/lag3二重特異性抗体 |
-
2018
- 2018-02-01 WO PCT/CN2018/074916 patent/WO2019148410A1/en active Application Filing
-
2019
- 2019-01-31 AU AU2019214977A patent/AU2019214977A1/en active Pending
- 2019-01-31 KR KR1020207024743A patent/KR20200115595A/ko not_active Application Discontinuation
- 2019-01-31 CN CN201980011259.7A patent/CN111670047A/zh active Pending
- 2019-01-31 WO PCT/US2019/015932 patent/WO2019152571A1/en unknown
- 2019-01-31 CA CA3089075A patent/CA3089075A1/en active Pending
- 2019-01-31 JP JP2020541785A patent/JP2021511806A/ja active Pending
- 2019-01-31 MX MX2020008122A patent/MX2020008122A/es unknown
- 2019-01-31 US US16/965,616 patent/US20210032342A1/en active Pending
- 2019-01-31 BR BR112020015498A patent/BR112020015498A8/pt unknown
- 2019-01-31 EP EP19747511.4A patent/EP3746120A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020128438A (ru) | 2022-03-03 |
WO2019148410A1 (en) | 2019-08-08 |
KR20200115595A (ko) | 2020-10-07 |
JP2021511806A (ja) | 2021-05-13 |
MX2020008122A (es) | 2020-09-18 |
BR112020015498A8 (pt) | 2023-02-07 |
US20210032342A1 (en) | 2021-02-04 |
CN111670047A (zh) | 2020-09-15 |
EP3746120A1 (en) | 2020-12-09 |
CA3089075A1 (en) | 2019-08-08 |
EP3746120A4 (en) | 2021-11-24 |
WO2019152571A1 (en) | 2019-08-08 |
BR112020015498A2 (pt) | 2020-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11072658B2 (en) | Anti-PD-1/LAG3 bispecific antibodies | |
AU2017331380B2 (en) | Anti-CD27 antibodies | |
EP3609922A2 (en) | Anti-sirp alpha antibodies | |
US20210032342A1 (en) | Anti-pd-1 antibodies | |
US20220251194A1 (en) | Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies | |
NL2018708B1 (en) | ANTI-SIRPα ANTIBODIES | |
RU2788095C2 (ru) | Анти-pd-1 антитела | |
US20230192876A1 (en) | Dosing regimen of anti-cd27 antibodies for treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HB | Alteration of name in register |
Owner name: MERCK SHARP & DOHME LLC Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP. |